FIELD: chemistry.
SUBSTANCE: invention relates to compound of formula (I) or its pharmaceutically acceptable salt, where A stands for -CHR7-, where R7 represents hydrogen, C1-6 alkyl, optionally substituted with substituent, selected from -OH, -OR8, where R8 represents C1-6 alkyl, -NH2, -COOH and -CONH2, C6 aryl-C1 alkyl, optionally substituted with 1-3 substituents, selected from-OH, -OP(=O)(OH)2, -OP(=O)(ONa)2 and C1-6 alkyl, 5-9-member heteroaryl- C1 alkyl, C6 cycloalkyl-C1 alkyl, C6 aryl or C6 cycloalkyl; G stands for -NR6- or -O-, where R6 is independently selected from C1-6 alkyl and C2-6 alkenyl; R1 stands for -Ra-R10; where Ra stands for C1-6 alkylene and R10 represents naphthyl or 9-10-member bicyclic condensed heteroaryl, optionally substituted with substituent selected from -NH2 and halogen; R2 represents -W21-W22-Rb-R20, where W21 represents -(CO)-; W22 represents -O- or -NH-; Rb represents bond or C1-6 alkylene, optionally substituted with C1-6 alkyl; and R20 represents C1-6 alkyl, C6-10 aryl, optionally substituted woth halogen, 5-6-member heteroaryl or C6 cycloalkyl; and R3 represents C1-6 alkyl; where "heteroaryl" represents monocyclic or bicyclic aromatic radical, where 1-3 ring atoms are heteroatoms, selected from nitrogen, oxygen and sulphur, and remaining ring atoms are carbon atoms and "bicyclic condensed" means ring, bound with another ring with formation of bicyclic structure, when atoms, common for both rings, are directly bound to each other. Invention also relates to particular compounds, method of treating or preventing disorder, modulated by Wnt-signaling pathway, agent, based on (I) 
formula compound, intermediate compound of formula (II) 
, method of obtaining formula (I) compound.
EFFECT: obtained are compounds, represented by formula (I), which possess useful biological properties.
32 cl, 3 dwg, 2 tbl, 209 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER AGENT | 2016 |
|
RU2729936C2 |
| NEW COMPOUNDS MIMETICS AND USING THEM | 2008 |
|
RU2457210C2 |
| NEW DERIVATIVES OF HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD FOR MODULATION OF AUTOIMMUNE DISEASES, METHOD FOR PREPARING THESE COMPOUNDS | 2000 |
|
RU2255937C2 |
| (6S,9AS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETHYDIN-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRASINO[2,1-C][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | 2014 |
|
RU2669805C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| COMPOUNDS AND METHODS FOR ENHANCING DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES, USING E3 UBIQUITIN LIGASE | 2013 |
|
RU2781452C2 |
| COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND METHOD FOR TREATMENT OF CYTOKINE-MEDIATED DISEASE | 2000 |
|
RU2298008C2 |
| MACROCYCLIC UREA AND SULPHAMIDE DERIVATIVES AS TAFIa INHIBITORS | 2009 |
|
RU2502736C2 |
| AMINOPYRAZINE COMPOUNDS WITH THE A2A ANTAGONIST PROPERTIES | 2015 |
|
RU2727805C2 |
| QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND USE THEREOF | 2012 |
|
RU2610262C2 |
